Reported resultsCompany-reported
What was reported
SOUTH SAN FRANCISCO, Calif. -- (August 3, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the third quarter ended June 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
What the evidence supports
Twist Bioscience published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $118.4 million | “"We continued our pattern of strong growth, reporting our fourteenth consecutive quarter of growth and exceeding guidance with revenue for the third quarter of fiscal 2026 of $118.4 million, growth of more than 23% compared to the third quarter of fiscal 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.” Mentions: revenue, guidance |
| $96.1 million | “•Revenue: Total revenues for the third quarter of fiscal 2026 grew 23% to $118.4 million compared to $96.1 million for the same period of fiscal 2025.” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineTwist Bioscience Reports Fiscal Third Quarter 2026 Financial ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Press release lead paragraphSOUTH SAN FRANCISCO, Calif. -- (August 3, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the third quarter ended June 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Amount stated in press release"We continued our pattern of strong growth, reporting our fourteenth consecutive quarter of growth and exceeding guidance with revenue for the third quarter of fiscal 2026 of $118.4 million, growth of more than 23% compared to the third quarter of fiscal 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Amount stated in press release•Revenue: Total revenues for the third quarter of fiscal 2026 grew 23% to $118.4 million compared to $96.1 million for the same period of fiscal 2025.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.